NCT06712823View on ClinicalTrials.gov

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Interventions
DRUG

atumelnant (CRN04894)

Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.

Trial Locations (9)

5000

RECRUITING

Crinetics Study Site, Córdoba

28557

ACTIVE_NOT_RECRUITING

Crinetics Study Site, Morehead City

55455

ACTIVE_NOT_RECRUITING

Crinetics Study Site, Minneapolis, Minnesota 55454, Minneapolis

80336

RECRUITING

Crinetics Study Site, Munich

18618-686

RECRUITING

Crinetics Study Site, Botucatu

05403-000

RECRUITING

Crinetics Study Site, São Paulo

00161

RECRUITING

Crinetics Study Site, Roma

CV22DX

RECRUITING

Crinetics Study Site, Birmingham

NW1 2BU

RECRUITING

Crinetics Study Site, London

Sponsors
All Listed Sponsors
lead

Crinetics Pharmaceuticals Inc.

INDUSTRY

NCT06712823 - An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 | Biotech Hunter | Biotech Hunter